Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker TGTX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia NCT07680946 · Schizophrenia Ublituximab | TGTX TG Therapeutics, Inc. | Phase 2 | Recruiting | 60 | Dec 12, 2028 | Registry ↗ |
| Oct 30, 2026 | A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xii… NCT06433752 · Relapsing Multiple Sclerosis, Multiple Sclerosis No Intervention | TGTX TG Therapeutics, Inc. | — | Recruiting | 2,000 | Apr 1, 2032 | Registry ↗ |
| Oct 30, 2026 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis NCT04130997 · Relapsing Multiple Sclerosis (RMS) Ublituximab | TGTX TG Therapeutics, Inc. | Phase 3 | Active, not recruiting | 1,100 | May 31, 2032 | Registry ↗ |
| Oct 29, 2026 | A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efg… NCT07673744 · Myasthenia Gravis Ublituximab, Placebo | TGTX TG Therapeutics, Inc. | Phase 2 | Recruiting | 120 | Jul 1, 2028 | Registry ↗ |
| Oct 29, 2026 | Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel NCT07577583 · B-cell Mediated Autoimmune Disorders No Intervention | TGTX TG Therapeutics, Inc. | — | Recruiting was not yet recruiting | 32 | Dec 1, 2039 | Registry ↗ |
| Oct 29, 2026 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered… NCT07503873 · Multiple Sclerosis Ublituximab, Ublituximab | TGTX TG Therapeutics, Inc. | Phase 2 | Recruiting | 350 | Jul 31, 2027 | Registry ↗ |
| Oct 29, 2026 | Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple S… NCT07220252 · Relapsing Multiple Sclerosis Ublituximab, Placebo | TGTX TG Therapeutics, Inc. | Phase 2/3 | Recruiting | 240 | Jan 1, 2030 | Registry ↗ |
| Oct 29, 2026 | A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Partici… NCT06433765 · Multiple Sclerosis No intervention | TGTX TG Therapeutics, Inc. | — | Recruiting | 728 | Mar 31, 2035 | Registry ↗ |
| Oct 27, 2026 | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated… NCT06680037 · B-cell Mediated Autoimmune Disorders Azercabtagene zapreleucel (azer-cel) | TGTX TG Therapeutics, Inc. | Phase 1 | Recruiting | 100 | Dec 1, 2026 | Registry ↗ |
| Oct 27, 2026 | A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk NCT06143514 · Relapsing Multiple Sclerosis No intervention | TGTX TG Therapeutics, Inc. | — | Active, not recruiting | 16 | Oct 31, 2026 | Registry ↗ |
| Oct 23, 2026 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effec… NCT07211633 · Relapsing Multiple Sclerosis Ublituximab, Ublituximab | TGTX TG Therapeutics, Inc. | Phase 3 | Active, not recruiting | 360 | Oct 31, 2026 | Registry ↗ |
| Oct 23, 2026 | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab NCT05877963 · Relapsing Multiple Sclerosis Ublituximab, Placebo | TGTX TG Therapeutics, Inc. | Phase 3 | Recruiting | 800 | Jan 21, 2027 | Registry ↗ |
| Dec 13, 2024 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and P… NCT02612311 · Chronic Lymphocytic Leukemia Obinutuzumab, Ublituximab | TGTX TG Therapeutics, Inc. | Phase 3 | Terminated | 603 | Feb 22, 2023 | Registry ↗ |
| Jul 31, 2024 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chron… NCT04806035 · CLL, SLL TG-1801, Ublituximab | TGTX TG Therapeutics, Inc. | Phase 1 | Terminated | 21 | Jun 12, 2024 | Registry ↗ |
| Jul 19, 2024 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malig… NCT03671590 · Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia TG-1701, Umbralisib | TGTX TG Therapeutics, Inc. | Phase 1 | Terminated | 172 | May 21, 2024 | Registry ↗ |
| Jul 3, 2024 | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who… NCT02742090 · Chronic Lymphocytic Leukemia Umbralisib | TGTX TG Therapeutics, Inc. | Phase 2 | Terminated | 51 | Jun 10, 2021 | Registry ↗ |
| Apr 19, 2024 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetocla… NCT03801525 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Ublituximab, Umbralisib | TGTX TG Therapeutics, Inc. | Phase 2/3 | Terminated | 277 | Dec 20, 2022 | Registry ↗ |
| Apr 8, 2024 | Study of TG-1801 in Subjects With B-Cell Lymphoma NCT03804996 · B-Cell Lymphoma TG-1801, Ublituximab | TGTX TG Therapeutics, Inc. | Phase 1 | Completed | 50 | Feb 21, 2024 | Registry ↗ |
| Jul 24, 2023 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic… NCT04016805 · Chronic Lymphocytic Leukemia Ublituximab, Umbralisib | TGTX TG Therapeutics, Inc. | Phase 2 | Terminated | 41 | May 22, 2022 | Registry ↗ |
| Jul 24, 2023 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma NCT03828448 · Follicular Lymphoma, Small Lymphocytic Lymphoma Ublituximab, Umbralisib | TGTX TG Therapeutics, Inc. | Phase 2 | Terminated | 34 | May 16, 2022 | Registry ↗ |
| Jun 23, 2023 | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent… NCT03364231 · Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia Umbralisib | TGTX TG Therapeutics, Inc. | Phase 2 | Completed | 21 | Feb 15, 2022 | Registry ↗ |
| Jun 22, 2023 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Parti… NCT02656303 · Chronic Lymphocytic Leukemia Ublituximab, Umbralisib | TGTX TG Therapeutics, Inc. | Phase 2 | Terminated | 116 | May 26, 2022 | Registry ↗ |
| Dec 21, 2022 | An Extension of the TG1101-RMS201 Trial NCT03381170 · Relapsing Remitting Multiple Sclerosis Ublituximab | TGTX TG Therapeutics, Inc. | Phase 2 | Completed | 48 | Nov 11, 2022 | Registry ↗ |
| Nov 21, 2022 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-… NCT01647971 · Non-Hodgkins Lymphoma, B-cell Lymphoma Ublituximab | TGTX TG Therapeutics, Inc. | Phase 1/2 | Completed | 39 | May 2015 | Registry ↗ |
| Oct 24, 2022 | Ublituximab + Ibrutinib in Select B-cell Malignancies NCT02013128 · Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Ublituximab, Ibrutinib | TGTX TG Therapeutics, Inc. | Phase 1/2 | Completed | 66 | Dec 2015 | Registry ↗ |
| Oct 20, 2022 | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-ref… NCT02535286 · Chronic Lymphocytic Leukemia, Richter Syndrome Umbralisib, ublituximab | TGTX TG Therapeutics, Inc. | Phase 1 | Completed | 27 | Nov 4, 2021 | Registry ↗ |
| Aug 22, 2022 | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma NCT03778073 · B-cell Non Hodgkin Lymphoma, Richter's Transformation Cosibelimab, Cosibelimab + Ublituximab + Bendamustine combi… | TGTX TG Therapeutics, Inc. | Phase 1 | Terminated | 18 | May 3, 2022 | Registry ↗ |
| Aug 22, 2022 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Su… NCT03379051 · Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Venetoclax, Umbralisib | TGTX TG Therapeutics, Inc. | Phase 1/2 | Terminated | 78 | May 26, 2022 | Registry ↗ |
| Jul 21, 2022 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currentl… NCT03207256 · Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma TGR-1202, TGR-1202 + Ublituximab | TGTX TG Therapeutics, Inc. | Phase 2 | Terminated | 51 | May 25, 2022 | Registry ↗ |
| Jul 21, 2022 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine an… NCT02793583 · Diffuse Large B-Cell Lymphoma, Follicular Lymphoma Ublituximab, Umbralisib | TGTX TG Therapeutics, Inc. | Phase 2/3 | Terminated | 710 | May 31, 2022 | Registry ↗ |
| May 20, 2022 | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Tr… NCT02301156 · Chronic Lymphocytic Leukemia Ublituximab, Ibrutinib | TGTX TG Therapeutics, Inc. | Phase 3 | Completed | 126 | Apr 1, 2020 | Registry ↗ |
| May 11, 2022 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies NCT01744912 · Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia Ublituximab, Lenalidomide | TGTX TG Therapeutics, Inc. | Phase 1 | Terminated | 10 | Feb 7, 2014 | Registry ↗ |
| Dec 6, 2021 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Mult… NCT03277261 · Relapsing Multiple Sclerosis (RMS) Ublituximab, Teriflunomide | TGTX TG Therapeutics, Inc. | Phase 3 | Completed | 549 | Jul 23, 2020 | Registry ↗ |
| Dec 6, 2021 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Mult… NCT03277248 · Relapsing Multiple Sclerosis (RMS) Ublituximab, Teriflunomide | TGTX TG Therapeutics, Inc. | Phase 3 | Completed | 545 | Aug 4, 2020 | Registry ↗ |
| Aug 23, 2021 | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Ma… NCT01767766 · Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia TGR-1202 | TGTX TG Therapeutics, Inc. | Phase 1 | Completed | 90 | Feb 2018 | Registry ↗ |
| Jul 15, 2021 | Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis NCT02738775 · Multiple Sclerosis Ublituximab, Placebo | TGTX TG Therapeutics, Inc. | Phase 2 | Completed | 49 | Sep 27, 2017 | Registry ↗ |
| Nov 5, 2019 | Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Mali… NCT02006485 · Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma Ublituximab + TGR-1202, Ublituximab + TGR-1202 + ibrutinib | TGTX TG Therapeutics, Inc. | Phase 1 | Completed | 160 | Oct 2019 | Registry ↗ |
| Oct 2, 2019 | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patien… NCT02574663 · Pancreatic Cancer, Colorectal Cancer TGR-1202, nab-paclitaxel + gemcitabine | TGTX TG Therapeutics, Inc. | Phase 1 | Completed | 66 | Aug 2018 | Registry ↗ |
| Oct 2, 2019 | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma… NCT02164006 · Hodgkin's Lymphoma TGR-1202 + brentuximab vedotin | TGTX TG Therapeutics, Inc. | Phase 1 | Completed | 16 | May 2016 | Registry ↗ |
| Oct 2, 2019 | TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients Wit… NCT02100852 · Chronic Lymphocytic Leukemia TGR-1202 + Obinutuzumab + Chlorambucil | TGTX TG Therapeutics, Inc. | Phase 1 | Completed | 19 | Nov 2017 | Registry ↗ |
40 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:26 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances